Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00661531 · ClinicalTrials.gov registry record · Phase 2

Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy

A Phase 2 study, sponsored by Georgetown University.

Terminated
Registry status
Phase 2
Development phase
11
Enrollment target

NCT00661531: Clinical Trial Phase 2 study, sponsored by Georgetown University.

NCT00661531 is a Phase 2 study that was terminated before completion, run by Georgetown University. The registered enrollment target is 11 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00661531, a Phase 2 study, was terminated before completion, sponsored by Georgetown University.

TERMINATED
Registry status
Phase 2
Development phase
11 participants
Enrollment target

Study Summary

This trial seeks to confirm the response rate for estrace treatment in a patients with hormone receptor positive metastatic breast cancer heavily pre-treated with modern endocrine therapies.

Primary Outcome

Progression free survival is defined as the time from assignment of treatment to the time of disease progression or death from any cause

Interventions

  • DRUG Anastrozole
  • DRUG Estrace

Trial Details

FieldValue
Enrollment Target 11 participants
Start Date 2008-04
Est. Completion 2015-06
Phase Phase 2
Georgetown University

227 total trials

Why NCT00661531 stopped before completion

NCT00661531 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).

The record links to 0 conditions, and to 2 interventions - of which Anastrozole is the first listed.

NCT00661531 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00661531 about?

NCT00661531 is a clinical study titled "Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy". This trial seeks to confirm the response rate for estrace treatment in a patients with hormone receptor positive metastatic breast cancer heavily pre-treated with modern endocrine therapies.

What is the current status of trial NCT00661531?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2008-04. Estimated completion is 2015-06.

What interventions are being tested in trial NCT00661531?

The interventions under investigation include: Anastrozole (DRUG), Estrace (DRUG).

Who is sponsoring clinical trial NCT00661531?

This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00661531's enrollment target sits among peer trials

11 1967th of 2000 higher than 33 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03114462 · 11 participants · Phase 1

    Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer

  • NCT06039709 · 11 participants · Phase 1

    Sonodynamic Therapy in Patients With Recurrent GBM

  • NCT06425380 · 11 participants · NA

    Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy

  • NCT06472661 · 11 participants · Early Phase 1

    FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00661531, the US trial registry maintained by the National Library of Medicine. NCT00661531 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.